Q2 and Partway Through

by EpicentRx | Jul 30, 2024 | Company Updates

EpicentRx is elated despite this newsletter being belated. It’s already the end of July – how time does fly! The unquestioned highlight of Q2 – and possibly of all 2024 – was the BOOM! heard ‘round the world from Dr. Anthony P. Conley’s ASCO oral presentation on...

VJ Oncology

by EpicentRx | Jun 21, 2024 | Media

YouTube video interviews with Dr. Lucy Kennedy from Cleveland Clinic Development of AdAPT-001, a novel TGF-β-trap-enhanced oncolytic virus Phase I/II trial of AdAPT-001, an oncolytic virus, and a checkpoint inhibitor in solid tumors The future of AdAPT-001 in patients...

Targeted Oncology

by EpicentRx | Jun 21, 2024 | Media

AHA (American Heart Association) Scientific Sessions 2022

by EpicentRx | Jun 14, 2024 | Conferences

November 5-7 , 2022 – McCormick Place, Chicago, IL View Poster

EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001, at the Upcoming 2024 ASCO Annual Meeting

by EpicentRx | May 23, 2024 | 2024, Press Releases

Data affirm positive immune effects of AdAPT-001 plus a checkpoint inhibitor in sarcomas and triple negative breast cancer with established checkpoint-inhibitor resistance The paucity of immune related adverse events suggests that AdAPT-001 may protect against them...